Efficacy and safety of transarterial chemoembolization (TACE) in combination with tislelizumab and TKIs versus TACE for the treatment of Intermediate and advanced HCC: A retrospective cohort study

被引：0
|
作者：
Han, Y. [1 ]
Tang, S. [1 ]
Gao, Y. [1 ]
Yan, X. [1 ]
Zhi, W. [1 ]
Gong, T. [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Dept Intervent Therapy, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.260
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
240P
引用
收藏
页码：S1494 / S1494
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of apatinib combined with transarterial chemoembolization (TACE) in treating patients with recurrent hepatocellular carcinoma
    Gu, Huiying
    Li, Jing
    You, Nan
    Wu, Ke
    Wang, Zheng
    Wang, Liang
    Zhu, Yinan
    Liu, Qinqin
    Peng, Xuehui
    Zheng, Lu
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (24)
  • [32] Efficacy and safety of transarterial chemoembolization (TACE) plus apatinib as compared with TACE alone for recurrent hepatocellular carcinoma: A prospective randomized controlled trial
    Gu, H.
    Li, J.
    You, N.
    Wu, K.
    Wang, Z.
    Wang, L.
    Zhu, Y.
    Liu, Q.
    Peng, X.
    Zheng, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S219 - S220
  • [33] Treatment of single hepatocellular carcinoma (HCC): Efficacy of transcatheter embolization/chemoembolization (TAE/TACE)
    Ferrandelli, Giovanni
    Miraglia, Roberto
    Vizzini, Giovanni
    TRANSPLANT INTERNATIONAL, 2007, 20 : 352 - 352
  • [34] Investigation of the Difference of Efficacy and Safety of TACE Combined with Sintilimab and Bevacizumab versus TACE Combined with Donafenib in Patients with Intermediate or Advanced Hepatocellular Carcinoma
    Sun, Yanjun
    Wang, Xing
    Ling, Changchun
    Yu, Yong
    Jia, Pengfei
    Lu, Xiaohua
    Zhao, Hui
    Gu, Zhuxin
    WIENER KLINISCHE WOCHENSCHRIFT, 2024, 136 : S412 - S412
  • [35] Drug-eluting bead transarterial chemoembolization (DEB-TACE) versus conventional transarterial chemoembolization (cTACE) in colorectal liver metastasis: Efficacy, safety, and prognostic factors
    Zhang, Hao
    Wu, Chunxue
    Chen, Miaoling
    Sun, Yuandong
    Han, Jianjun
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (06) : 1525 - 1532
  • [36] Efficacy and safety of anlotinib combined with TACE among patients with intermediate and advanced-stage hepatocellular carcinoma (HCC)
    Zheng, Lin
    Li, Hailiang
    Guo, Chenyang
    Hu, Hongtao
    Li, Fangkun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [37] Efficacy and safety analysis of TACE plus Donafenib plus Toripalimab versus TACE plus Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study
    Lu, Haohao
    Liang, Bin
    Xia, Xiangwen
    Zheng, Chuansheng
    BMC CANCER, 2023, 23 (01)
  • [38] Conventional transarterial chemoembolization versus doxorubicin bead transarterial chemoembolization for the treatment of hepatocellular carcinoma, a retrospective cohort study
    Bloom, Stephen
    Cheng, Richard Kai Yuan
    Lim, Lucy
    Gow, Paul
    Lubel, John S.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 70 - 71
  • [39] Efficacy of the combination of transarterial chemoembolization (TACE) and immunotherapy of atezolizumab plus bevacizumab in patients before liver resection and transplantation (OTP) with hepatocellular carcinoma (HCC)
    Nasonova, K. A.
    Zagidullina, A. A.
    Breder, V. V.
    Khagazheeva, M.
    Kudashkin, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S78 - S78
  • [40] Efficacy and safety of TACE combined with anlotinib compared with TACE alone among patients with intermediate or advanced hepatocellular carcinoma (HCC): A randomized, controlled, phase II clinical study.
    Zeng, Hui
    Shao, Guoliang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 581 - 581
12345